Brokerages forecast that Sientra Inc (NASDAQ:SIEN) will report $16.20 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Sientra’s earnings, with the highest sales estimate coming in at $16.50 million and the lowest estimate coming in at $16.00 million. Sientra reported sales of $9.82 million in the same quarter last year, which would suggest a positive year over year growth rate of 65%. The company is scheduled to report its next earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Sientra will report full-year sales of $67.37 million for the current year, with estimates ranging from $65.30 million to $68.70 million. For the next year, analysts expect that the company will post sales of $96.40 million per share, with estimates ranging from $93.30 million to $99.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Sientra.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.04). The business had revenue of $17.55 million during the quarter, compared to analysts’ expectations of $15.30 million. Sientra had a negative net margin of 131.16% and a negative return on equity of 151.47%.
Shares of Sientra opened at $20.89 on Friday, according to MarketBeat.com. The stock has a market capitalization of $619.15 million, a P/E ratio of -7.41 and a beta of -0.92. Sientra has a one year low of $8.79 and a one year high of $26.79. The company has a quick ratio of 0.71, a current ratio of 3.06 and a debt-to-equity ratio of 0.27.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its stake in Sientra by 94.3% during the second quarter. BlackRock Inc. now owns 1,490,587 shares of the medical instruments supplier’s stock valued at $29,081,000 after buying an additional 723,279 shares in the last quarter. Gilder Gagnon Howe & Co. LLC raised its position in shares of Sientra by 29.8% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,373,007 shares of the medical instruments supplier’s stock worth $26,787,000 after purchasing an additional 315,408 shares during the period. Cannell Capital LLC raised its position in shares of Sientra by 15.8% during the 1st quarter. Cannell Capital LLC now owns 1,158,485 shares of the medical instruments supplier’s stock worth $11,191,000 after purchasing an additional 158,058 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Sientra during the 2nd quarter worth approximately $20,375,000. Finally, Bamco Inc. NY raised its position in shares of Sientra by 20.0% during the 1st quarter. Bamco Inc. NY now owns 588,100 shares of the medical instruments supplier’s stock worth $5,681,000 after purchasing an additional 98,000 shares during the period. Hedge funds and other institutional investors own 60.47% of the company’s stock.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Story: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.